Pamela L Lutsey1, Faye L Norby1, Neil A Zakai2, Richard F MacLehose1, Lin Y Chen3, Surbhi Shah4, Yvonne H Datta4, Alvaro Alonso5. 1. a Division of Epidemiology & Community Health , School of Public Health, University of Minnesota , Minneapolis , MN, USA. 2. b Division of Hematology/Oncology, Department of Medicine & Department of Pathology and Laboratory Medicine , Larner College of Medicine at the University of Vermont , Colchester , VT , USA. 3. c Cardiovascular Division , Department of Medicine , University of Minnesota Medical School , Minneapolis , MN , USA. 4. d Division of Hematology, Oncology and Transplantation, Department of Medicine , University of Minnesota Medical School , Minneapolis , MN , USA. 5. e Department of Epidemiology , Rollins School of Public Health, Emory University , Atlanta , GA , USA.
Abstract
OBJECTIVE: Oral anticoagulation (OAC) prescribed to AF patients for the prevention of cardioembolic complications likely has the added benefit of preventing venous thromboembolism (VTE). This study evaluated, among AF patients who are anticoagulated, whether type of OAC was associated with subsequent VTE risk. METHODS: Non-valvular AF patients prescribed OACs between 2010 and September 2015 were identified via the MarketScan administrative claims databases. OACs included warfarin and direct OACs (DOACs: dabigatran, rivaroxaban, and apixaban). Incident VTE was defined by ICD-9-CM codes. Patients were matched on age, sex, CHA2DS2-VASc, and high-dimensional propensity scores. The final analysis included 117,912 AF patients. RESULTS: In total, 1357 VTE events accrued over a mean follow-up of 484 days. In multivariable-adjusted, propensity score-matched Cox models, relative to new users of warfarin, risk of incident VTE was lower among new users of dabigatran [hazard ratio (95% confidence interval) = 0.55 (0.47-0.66)] and apixaban [0.51 (0.39-0.68)], but similar among new users of rivaroxaban [1.01 (0.87-1.19)]. In head-to-head DOAC comparisons, VTE risk was lower among users of dabigatran [0.48 (0.36-0.64)] and apixaban [0.61 (0.47-0.78)] vs rivaroxaban. Findings were mostly similar across patient sub-groups. CONCLUSIONS: In this large practice-based population of AF patients prescribed OACs for primary prevention of stroke and systemic embolization, subsequent risk of VTE was lowest among those prescribed apixaban and dabigatran, while risk was similar with prescriptions for warfarin and rivaroxaban. Among AF patients prescribed OACs, lowering the risk of VTE may be an additional benefit of apixaban and dabigatran, beyond the reduced bleeding risk observed in randomized clinical trials.
OBJECTIVE: Oral anticoagulation (OAC) prescribed to AF patients for the prevention of cardioembolic complications likely has the added benefit of preventing venous thromboembolism (VTE). This study evaluated, among AF patients who are anticoagulated, whether type of OAC was associated with subsequent VTE risk. METHODS: Non-valvular AF patients prescribed OACs between 2010 and September 2015 were identified via the MarketScan administrative claims databases. OACs included warfarin and direct OACs (DOACs: dabigatran, rivaroxaban, and apixaban). Incident VTE was defined by ICD-9-CM codes. Patients were matched on age, sex, CHA2DS2-VASc, and high-dimensional propensity scores. The final analysis included 117,912 AF patients. RESULTS: In total, 1357 VTE events accrued over a mean follow-up of 484 days. In multivariable-adjusted, propensity score-matched Cox models, relative to new users of warfarin, risk of incident VTE was lower among new users of dabigatran [hazard ratio (95% confidence interval) = 0.55 (0.47-0.66)] and apixaban [0.51 (0.39-0.68)], but similar among new users of rivaroxaban [1.01 (0.87-1.19)]. In head-to-head DOAC comparisons, VTE risk was lower among users of dabigatran [0.48 (0.36-0.64)] and apixaban [0.61 (0.47-0.78)] vs rivaroxaban. Findings were mostly similar across patient sub-groups. CONCLUSIONS: In this large practice-based population of AF patients prescribed OACs for primary prevention of stroke and systemic embolization, subsequent risk of VTE was lowest among those prescribed apixaban and dabigatran, while risk was similar with prescriptions for warfarin and rivaroxaban. Among AF patients prescribed OACs, lowering the risk of VTE may be an additional benefit of apixaban and dabigatran, beyond the reduced bleeding risk observed in randomized clinical trials.
Authors: Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245
Authors: Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores Journal: Chest Date: 2016-01-07 Impact factor: 9.410
Authors: David J Graham; Marsha E Reichman; Michael Wernecke; Ya-Hui Hsueh; Rima Izem; Mary Ross Southworth; Yuqin Wei; Jiemin Liao; Margie R Goulding; Katrina Mott; Yoganand Chillarige; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman Journal: JAMA Intern Med Date: 2016-11-01 Impact factor: 21.873
Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: Gary Raskob; Walter Ageno; Alexander T Cohen; Marjolein P A Brekelmans; Michael A Grosso; Annelise Segers; Guy Meyer; Peter Verhamme; Philip S Wells; Min Lin; Shannon M Winters; Jeffrey I Weitz; Harry R Büller Journal: Lancet Haematol Date: 2016-03-22 Impact factor: 18.959
Authors: Elizabeth J Bell; Pamela L Lutsey; Saonli Basu; Mary Cushman; Susan R Heckbert; Donald M Lloyd-Jones; Aaron R Folsom Journal: Am J Med Date: 2015-11-18 Impact factor: 4.965
Authors: Sam Schulman; Ajay K Kakkar; Samuel Z Goldhaber; Sebastian Schellong; Henry Eriksson; Patrick Mismetti; Anita Vedel Christiansen; Jeffrey Friedman; Florence Le Maulf; Nuala Peter; Clive Kearon Journal: Circulation Date: 2013-12-16 Impact factor: 29.690
Authors: Mary Cushman; Albert W Tsai; Richard H White; Susan R Heckbert; Wayne D Rosamond; Paul Enright; Aaron R Folsom Journal: Am J Med Date: 2004-07-01 Impact factor: 4.965
Authors: Alenka Premuš Marušič Kovačič; Martin Caprnda; Aleš Mrhar; Peter Kubatka; Igor Locatelli; Barbora Zolakova; Ludovit Gaspar; Robert Prosecky; Peter Kruzliak; Robert Staffa; Luis Rodrigo; Jozef Radonak; Danijel Petrovič Journal: Eur J Clin Pharmacol Date: 2019-02-05 Impact factor: 2.953
Authors: Pamela L Lutsey; Neil A Zakai; Richard F MacLehose; Faye L Norby; Rob F Walker; Nicholas S Roetker; Terrence J Adam; Alvaro Alonso Journal: Br J Haematol Date: 2019-03-28 Impact factor: 6.998